| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Inno-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.36 |
| 52 Week High | zł1.09 |
| 52 Week Low | zł0.33 |
| Beta | 1.19 |
| 11 Month Change | 0% |
| 3 Month Change | -11.95% |
| 1 Year Change | -66.26% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| WQ3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 0.9% |
| 1Y | -66.3% | -11.2% | 5.7% |
Return vs Industry: WQ3 underperformed the German Life Sciences industry which returned -11.2% over the past year.
Return vs Market: WQ3 underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| WQ3 volatility | |
|---|---|
| WQ3 Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: WQ3 has not had significant price volatility in the past 3 months.
Volatility Over Time: WQ3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10 | Jacek Wojciechowicz | www.inno-gene.pl |
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
Inno-Gene S.A. Fundamentals Summary
| WQ3 fundamental statistics | |
|---|---|
| Market cap | €2.58m |
| Earnings (TTM) | -€318.76k |
| Revenue (TTM) | €110.70k |
23.3x
P/S Ratio-8.1x
P/E RatioIs WQ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WQ3 income statement (TTM) | |
|---|---|
| Revenue | zł474.00k |
| Cost of Revenue | zł667.50k |
| Gross Profit | -zł193.49k |
| Other Expenses | zł1.17m |
| Earnings | -zł1.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 12, 2024
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -40.82% |
| Net Profit Margin | -287.96% |
| Debt/Equity Ratio | 6.8% |
How did WQ3 perform over the long term?
See historical performance and comparison